Recent studies suggest the emergence of potential disease-modifying drugs for Parkinson's disease, including GLP-1 and an anti-synuclein antibody. Prasinezumab, a monoclonal antibody, may reduce motor signs progression in rapidly progressing Parkinson's disease cases. A monthly antibody infusion could slow Parkinson's disease progression, particularly in advanced symptom cases.
New drug may slow rapid progression of #Parkinson'sDisease @nresearchnews @NatureMedicine https://t.co/IbOAmIdEcd
An exploratory analysis of data from a phase 2 clinical trial reported in @NatureMedicine shows that prasinezumab, a monoclonal antibody, may reduce signs of motor deterioration in individuals with Parkinson’s disease who have rapidly progressing disease. https://t.co/zIfFcxoqoo
A monthly antibody infusion may slow the progression of Parkinson’s disease, but perhaps only among people with advanced symptoms. https://t.co/6wqdUpKPJs
Exploratory analysis of the 1-year clinical trial PASADENA in individuals with early-stage #ParkinsonsDisease suggests that prasinezumab might reduce motor signs progression to a greater extent in those with more rapidly progressing disease. #PD @AzadBonni https://t.co/nNMPeXrhKO
A monthly antibody infusion may be the first treatment that slows the progression of Parkinson’s disease, but perhaps only among people with advanced symptoms. https://t.co/2U0v21EWjy
There's never been a disease-modifying drug for Parkinson's disease to slow its progression. Now there may be two emerging. —GLP-1 https://t.co/SbxYpnzfB2 @NEJM —anti-synuclein antibody https://t.co/IMoSkQc1Qw @NatureMed https://t.co/XIWiDYeTvE
Parkinson’s arrived in her 20s. Now, she's thankful for a procedure she was once scared of. https://t.co/pKJLxOovEy